




Figure 1

Figure 2A. Viral Binding




Figure 2B Viral Binding
(With Z3G1)





Figure 3A Full-length M2 variant binding

Amino Acid Sequences of Extracellular Domains of M2 Variants



Extracellular sequence of D20 is identical to #19, HK483 to #29, and VN1203 to

Figure 3B Full-length M2 variant binding
(with Z3G1)




Figure 3C Full-length M2 variant binding




Figure 4A Alanine Scanning Mutagenesis (with Z3G1)




Figure 4B. Alanine Scanning Mutagenesis




Figure 5. Epitope Blocking




Figure 6A

Cross reactivity binding of anti-M2 antibodies to variant M2 peptides

SeqNo	Name	Size	Description	14C2	8H10	23K12	2A9
1	M2	23 aa	SLLTEVETPIRNEWGCRCDSSD	+	-	-	-
2	M2SG	23 aa	SLLTEVETPIRSEWGCRCDSDG	+	-	-	-
3	M2EG	23 aa	SLLTEVETPIRNEWECRCNGSSD	+	-	-	-
4	M2P	23 aa	SLPTEVETPIRNEWGCRCDSSD	+	-	-	-
5	M2G	23 aa	SLLTEVETPIRNEWGCRCDSSD	+	-	-	-
6	M2DLTGS	23 aa	SLLTEVDLIRNGWGCRCDSSD	-	-	+	-
7	M2KNS	23 aa	SLLTEVETPIRKEWGCRCDSSD	+	-	-	-
8	M2LGS	23 aa	SLLTEVETLIRNGWGCRCDSSD	-	-	-	-
9	M2LTGS	23 aa	SLLTEVETLTKNGWGCRCDSSD	-	-	-	-
10	M2SY	23 aa	SLLTEVETPIRSEWGCRYNDSSD	+	-	-	-
11	M2TGEKS	23 aa	SLLTEVETPTRNGWECKCDSSD	+	-	-	-
12	M2HTGEKS	23 aa	SLLTEVETHTRNGWECKCDSSD	-	-	-	-
13	M2KTGEKS	23 aa	SLLTEVKTPTRNGWECKCDSSD	-	-	-	-
14	M2LTGS	23 aa	SLLTEVETLIRNGWGCRCDSSD	-	-	+	-
15	M2TDGEKS	23 aa	SLLTEVETPTRDNGWECKCDSSD	+	-	-	-
16	M2TGS	23 aa	SLLTEVETPTRNGWGCRCDSSD	+	-	W	-
17	M2TGEK	23 aa	SLLTEVETPTRNGWECKCDSSD	+	-	-	-
18	M2LTGEKS	23 aa	SLLTEVETLIRNGWECKCDSSD	-	-	W	-
19	M2K	23 aa	SLLTEVETPIRNEWGCKCDSSD	+	W	+	-
20	M2FG	23 aa	SFLTEVETPIRNEWGCRCDSSD	+	W	-	-
21	M2TGE	23 aa	SLLTEVETPTRNGWECKCDSSD	+	-	-	-
22	M2KGNS	23 aa	SLLTEVETPIRKGWECNCSDSSD	+	-	-	-
23	M2TES	23 aa	SLLTEVETPTRNEWECRCSDSSD	+	-	-	-
24	M2GHTGKS	23 aa	SLLTGVEHTRNGWGCKCDSSD	-	-	-	-
25	M2PHTGS	23 aa	SLLPEVETHTRNGWGCRCDSSD	-	-	-	-

Percentage compared relative to binding to wild-type peptide (Seq 1)

Note: mAbs were tested at 5 µg/ mL

> 25 % - no binding

25 - 40 % W weak binding

> 40 % + positive binding


Figure 6B

Binding activity of M2 antibodies to truncated M2 peptides

Sample	Name	Size	Description	14C2	8H10	*3H12	2N9
1	M2	23 aa	SLLTEVETPIRNEWGRCNDSSD	3.85	0.11	0.22	0.06
26	M16	16 aa	LLTEVETPIRNEWGCR	3.94	0.09	0.21	0.09
27	M15	15 aa	LTEVETPIRNEWGCR	3.95	0.09	0.21	0.09
28	M12	12 aa	VETPIRNEWGCR	0.15	0.09	0.20	0.09
29	CM17	17 aa	ETPIRNEWGRCNDSSD	0.19	0.11	0.34	0.11
30	CM16	16 aa	TPIRNEWGRCNDSSD	0.23	0.13	0.35	0.12
31	CM15	15 aa	PIRNEWGRCNDSSD	0.19	0.12	0.34	0.11
32	CM14	14 aa	IRNEWGRCNDSSD	0.23	0.14	0.36	0.13
33	CM13	13 aa	RNEWGRCNDSSD	0.22	0.14	0.34	0.13
34	CM12	12 aa	NEWGRCNDSSD	0.27	0.14	0.39	0.14
35	NM17	17 aa	SLLTEVETPIRNEWGCR	3.99	0.26	0.58	0.10
36	NM16	16 aa	SLLTEVETPIRNEWGC	3.90	0.29	0.62	0.09
37	NM15	15 aa	SLLTEVETPIRNEWG	3.97	0.12	0.30	0.11
38	NM14	14 aa	SLLTEVETPIRNEW	3.97	0.11	0.24	0.09
39	NM13	13 aa	SLLTEVETPIRNE	0.18	0.11	0.25	0.10
40	NM12	12 aa	SLLTEVETPIRN	0.20	0.10	0.24	0.09
41	NM11	11 aa	SLLTEVETPIR	0.21	0.13	0.30	0.12
42	NM10	10 aa	SLLTEVETPI	0.17	0.10	0.24	0.10
43	NM8	8 aa	SLLTEVET	0.15	0.10	0.20	0.09
44	NM7	7 aa	SLLTEVE	0.14	0.10	0.20	0.08
45	NM9	9 aa	SLLTEVETP	0.21	0.12	0.30	0.19
46	M2e	24 aa	MSLLTEVETPIRNEWGRCNDSSD	3.98	0.13	0.43	0.10
CMV	HVIR1			0.16	0.11	0.21	3.99

Note: mAbs were tested at 5 µg/ mL

Figure 7 High path prophylactic in vivo study



SPDQ M2e mAbs Appear to Bind Highly Conserved N-Terminal Region of M2e






Figure 8





16/16

FIGURE 11

